Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania

Autor:	Habib O. Ramadhani, Sendui Ole-Nguyaine, Humphrey J. Shao, Christopher W. Woods, John A. Crump, Andrew M. Moon, Leonard O. Uiso, John F. Shao, John Bartlett, Nathan M. Thielman, Rehema A. Kiwera
Rok vydání:	2009
Předmět:	Adult Male medicine.medical_specialty Anti-HIV Agents Immunology Fixed-dose combination HIV Infections Pilot Projects Pharmacology Gastroenterology Tanzania 03 medical and health sciences Zidovudine 0302 clinical medicine Pharmacotherapy Abacavir Immune Reconstitution Inflammatory Syndrome Virology Internal medicine medicine Humans Tuberculosis 030212 general & internal medicine Clinical Trials/Clinical Studies Adverse effect 0303 health sciences 030306 microbiology business.industry Abacavir/Lamivudine/Zidovudine Lamivudine Viral Load Dideoxynucleosides 3. Good health CD4 Lymphocyte Count Treatment Infectious Diseases HIV-1 Drug Therapy Combination Female business Viral load medicine.drug
Zdroj:	AIDS research and human retroviruses. 25(12)
ISSN:	1931-8405
Popis:	Fixed dose combination abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) among HIV-1 and tuberculosis (TB)-coinfected patients was evaluated and outcomes between early vs. delayed initiation were compared. In a randomized, pilot study conducted in the Kilimanjaro Region of Tanzania, HIV-infected inpatients with smear-positive TB and total lymphocyte count
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65d82d007cb60062f2f24ec4acc5a56d https://pubmed.ncbi.nlm.nih.gov/20001518 Zobrazit plný text záznamu